Minovia Therapeutics Archives

Home / Posts tagged Minovia Therapeutics

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

HAIFA, Israel, Aug. 27, 2025 (Korea Bizwire) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of [...]

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatric Designation granted MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April 03, 2025 (Korea Bizwire) – Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. [...]

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow reconstitution potential of patient derived hematopoietic stem cells In vitro data also demonstrated improved ability to differentiate to erythroid cells, supporting potential for improvement in biomarkers of anemia HAIFA, Israel, Sept. 26 (Korea Bizwire) [...]

Minovia Therapeutics Appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as Board Member

TIRAT HACARMEL, Israel, Jan. 5 (Korea Bizwire) – Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a [...]

Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023

WOBURN, Mass. and HAIFA, Israel, Jan. 3 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Time: 9:45 AM PST Track: Franciscan C (Ballroom Level) Biotech [...]

Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases

WOBURN, Mass. and HAIFA, Israel, Dec. 21 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine. The study was conducted in collaboration with global leaders [...]